Mode
Text Size
Log in / Sign up
Phase 4 N=150 Randomized Treatment

Diabetes in the Elderly: Prospective Study

Diabetes · Hyperglycemia

Enrolled (actual)
150
Serious AEs
14.0%
Results posted
Dec 2014
Primary outcome: Primary: Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL — 28; 31 percentage of participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Insulin Glargine (Drug); Insulin (Drug); Insulin glulisine (Drug)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
Guillermo Umpierrez
Primary completion
Dec 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL
28; 31
PRIMARY
Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL
0; 1
PRIMARY
Mean of Weekly Fasting Blood Glucose Concentration
130; 123
SECONDARY
Mean Blood Glucose Concentration
198.2; 191.8
SECONDARY
Mean of Glycosylated Hemoglobin (hbA1c)
6.7; 6.3
SECONDARY
Mean of Daily Blood Glucose Concentration
163.0; 137.7
SECONDARY
Mean of Glycosylated Hemoglobin (hbA1c)
6.7; 6.3
SECONDARY
Mean of Glycosylated Hemoglobin (hbA1c)
6.7; 6.3

Summary

Diabetes is highly prevalent in the elderly, afflicting about 20% of older adults aged 65-75 years and 40% of adults >80years of age. It is expected that the number of elderly people suffering from diabetes will increase in the future, as general life expectancy is increasing. Nursing home residents with diabetes have higher rates of serious comorbidities and have greater activity of daily living dependencies than other residents without diabetes. In addition, persons with diabetes have higher risk of hypertension, heart disease, stroke depression, cognitive impairment, and cardiovascular mortality than individuals without diabetes. There are a few retrospective studies in elderly patients analyzing quality of diabetes care and glycemic control adjusted for medications and presence of co-morbidities in long-term care facilities; however, no previous randomized controlled trials have demonstrated benefits of glycemic control on clinical outcome, quality of life, and rate of acute metabolic complications (hyperglycemia and hypoglycemic events) in long-term care facilities. In addition, it is not known whether the use of basal insulin is superior to treatment with sliding scale insulin (SSI) in long-term care facility residents with type 2 diabetes. Accordingly, the investigators propose to conduct a prospective randomized control trial comparing the efficacy and safety of the basal (glargine) insulin regimen and sliding scale regular insulin in the management of nursing home patients with T2DM.

Eligibility Criteria

Inclusion Criteria

  • Males or females > 60 years of age.
  • Blood glucose > 150 mg/dl and A1C > 7.5%.
  • A known history of T2DM, receiving either diet alone, oral monotherapy, or with any combination of oral antidiabetic agents (metformin, sulfonylureas, repaglinide, nateglinide, pioglitazone, rosiglitazone, sitagliptin).
  • Patients admitted for non-cardiac elective or emergency surgery or trauma.

Exclusion Criteria

  • Subjects with increased blood glucose concentration, but without a known history of diabetes (stress hyperglycemia).
  • Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state (26).
  • Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, or impaired renal function (creatinine ≥ 3.5 mg/dl).
  • Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01131052). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search